

# Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein

Catalog No.: RP01388 **Recombinant**

## Sequence Information

Species	Gene ID	Swiss Prot
Human	8795	O14763-1

### Tags

C-hFc&His

### Synonyms

CD262;DR5;KILLER;KILLER/DR5;TRAIL-R2;TRAILR2;TRICK2;TRICK2A;TRICK2B;TRICKB;ZTNFR9;TNFRSF10B

## Product Information

Source	Purification
HEK293 cells	> 95% by SDS-PAGE.

Calculated MW	Observed MW
41.07 kDa	50-55 kDa

### Endotoxin

<0.1EU/μg

### Formulation

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize freeze-thaw cycles.

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Background

This protein is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

## Basic Information

### Description

Active Recombinant Human TNFRSF10B/DR5/TRAIL-R2 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ile56-Glu182) of human DR5/TRAIL R2 (Accession #NP\_003833.3) fused with a Fc, 6×His tag at the C-terminus.

### Bio-Activity

1. Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF10B at 1 μg/mL (100 μL/well) can bind Human TNFSF10 with a linear range of 0.1-11.7 ng/mL. 2. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L\_x001e\_929 mouse fibroblast cells treated with TRAIL. The ED<sub>50</sub> for this effect is 30-120 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.


### Storage

Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.


After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.

Avoid repeated freeze/thaw cycles.


## Validation Data




Recombinant Human TNFRSF10B/DR5/TRAIL-R2 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 50kDa.



The purity of Human DR5/TRAIL R2 Protein (Cat. RP01388) was greater than 90% as determined by SEC-HPLC.



Immobilized Human TNFRSF10B at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind Human TNFSF10 with a linear range of 0.1-11.7 ng/mL.



Recombinant Human TNFRSF10B inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The  $ED_{50}$  for this effect is 30-120 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.